LENACAPAVIR TABLET

LENACAPAVIR TABLET Specification

Packaging Type
BOX

Brand Name
LENACAPAVIR

Pacakaging (Quantity Per Box)
1

Indication
HIV

Dosage Form
300

Origin of Medicine
IMPORTED

Life Span
24 MONTHS

Salt Composition
LENACAPAVIR

Drug Type
Specific Drug

Ingredients
Sunlenca (lenacapavir) is a capsid antiviral inhibitor indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) in adult patients. Sunlenca (lenacapavir) was approved by the FDA2, EMA3 and MHRA. enacapavir is a breakthrough, first-in-class HIV capsid inhibitor. Administered as a subcutaneous injection under the skin of the abdomen or thigh twice a year, it is used for both HIV treatment (with other antiretrovirals) and HIV prevention (PrEP). [1, 2, 3, 4, 5] 1. Key Uses & Approvals HIV Prevention (PrEP): Recommended by the World Health Organization and approved in major markets, it is one of the most effective prevention tools available, requiring only two doses a year. [1, 2] HIV Treatment: Marketed as Sunlenca, it is approved for heavily treatment-experienced adults with multi-drug resistant HIV-1 whose current regimens are failing. [1]

Physical Form
Tablets

Function
Anti-Viral

Recommended For
ADULTS

Dosage
300

Dosage Guidelines
300MG

Suitable For
Adults

Quantity
1 Boxes

Storage Instructions
COOL

LENACAPAVIR TABLET Trade Information

Minimum Order Quantity
1 pack

FOB Port
INDIA

Payment Terms
Paypal, Cash in Advance (CID), Cheque, Delivery Point (DP), Letter of Credit at Sight (Sight L/C), Telegraphic Transfer (T/T), Western Union

Supply Ability
100 Per Month

Delivery Time
2 Days

Sample Available
Yes

Sample Policy
If order is confirmed we will reimburse the sample cost

Packaging Details
BOX

Main Export Market(s)
Eastern Europe, Asia, Australia, Central America, North America, South America, Western Europe, Middle East, Africa

Certifications
GMP

About LENACAPAVIR TABLET

Sunlenca (lenacapavir) is a capsid antiviral inhibitor indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) in adult patients.

Sunlenca (lenacapavir) was approved by the FDA2, EMA3 and MHRA.

Lenacapavir is primarily administered as a twice-yearly injection for HIV, though oral 300 mg tablets are occasionally used during the initiation of therapy. In India, generic versions and imports of Lenacapavir (Sunlenca) for heavily treatment-experienced HIV cost roughly

Pack Size: Typically supplied as a box of 5 tablets (300 mg).
Sourcing: Because these are specialized medications for multidrug-resistant HIV, they are often sourced through specialized pharmaceutical distributors rather than retail pharmacies

Disclaimer: Trademark shown are property of their respective owners and We do not lay any claim on them.

Tell us about your requirement